Call us 24/7

Clinical trials

Search our clinical trials

Cancer Treatment Centers of America® (CTCA) is committed to providing new and innovative treatments for our cancer patients whenever possible. This includes enrolling qualified patients in carefully selected clinical trials for cancer. Clinical trials are a key testing ground for determining the effectiveness and safety of new treatments and drugs for cancer and other diseases. Our doctors may recommend that cancer patients enroll in cancer clinical trials if they meet specific criteria. Cancer trials may offer patients access to treatment options that would otherwise be unavailable to them. Talk to your doctor about whether a cancer trial is a good option for you and ask about the risks and various requirements involved. Use the tool below to find a CTCA® clinical trial for your cancer type.

Filters

74 Clinical Trials

This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.

This study will evaluate the safety and tolerability profile of GSK2857916 when administered in combination with approved regimens of either lenalidomide plus dexamethasone [Len/Dex (Arm A)] or bortezomib plus dexamethasone [Bor/Dex (Arm B)] in participants with RRMM, i.e., those who have relapsed or who are refractory to at least one line of approved therapy.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This study is a phase 1, open-label, multi-center dose escalation and dose expansion study in patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma.

The primary objectives will be to determine the efficacy of MT-3724 as monotherapy in subjects with relapsed or refractory DLBCL based on the overall response rate (ORR) by the revised Lugano Classification for lymphoma adjusted according to lymphoma response to immunomodulatory therapy criteria (LYRIC) hereinafter referred to as “revised Lugano Criteria” (Cheson et al, 2014, 2016).

The purpose of this study is to evaluate the safety and tolerability of MT-3724 in combination with gemcitabine and oxaliplatin (GEMOX) in subjects with relapsed or refractory B-Cell NHL.

The purpose of this study is to evaluate the safety and tolerability of MT-3724 in combination with Lenalidomide in subjects with relapsed or refractory B-Cell NHL.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This randomized, phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned (recurrent) after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with recurrent platinum-resistant ovarian cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a global, multi-center, randomized, double-blind, controlled phase 3 study in patients with newly diagnosed, stage III or IV non-mucinous epithelial ovarian, fallopian tube, or peritoneal cancer (collectively referred to as ovarian cancer).

The purpose of this study is to confirm the recommended phase II dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment.